Lisdexamfetamine (Commercial)

Lisdexamfetamine (Commercial)
Product Description

A broad-strength capsule opportunity associated with attention deficit hyperactivity disorder.

Dosage form: Hard capsule Strengths: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg Therapeutic area: Nervous system Key indication: Attention deficit hyperactivity disorder Product class: Psychoanaleptic Dossier status: Available Stability coverage: Zone IVb Six available strengths provide a broad product presentation for partners building or expanding a central nervous system portfolio.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Specifications
  • Details
    A broad-strength capsule opportunity associated with attention deficit hyperactivity disorder.

    Dosage form: Hard capsule Strengths: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg Therapeutic area: Nervous system Key indication: Attention deficit hyperactivity disorder Product class: Psychoanaleptic Dossier status: Available Stability coverage: Zone IVb Six available strengths provide a broad product presentation for partners building or expanding a central nervous system portfolio.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist

More Products from Medis ehf. (26)

  • Esomeprazole Capsules (Reformulation)

    Product Esomeprazole Capsules (Reformulation)

    A gastro-resistant capsule reformulation associated with gastroesophageal reflux disease.

    Dosage form: Gastro-resistant capsule Strengths: 20 mg and 40 mg Therapeutic area: Alimentary tract and metabolism Key indication: Gastroesophageal reflux disease Product class: Peptic ulcer and gastro-oeso...
  • Esomeprazole Tablets (Commercial)

    Product Esomeprazole Tablets (Commercial)

    An established gastroenterology opportunity available in two widely recognised strengths.

    Dosage form: Gastro-resistant tablet Strengths: 20 mg and 40 mg Therapeutic area: Alimentary tract and metabolism Key indications: Duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux d...
  • Ferric Carboxymaltose (Commercial)

    Product Ferric Carboxymaltose (Commercial)

    An intravenous product opportunity for partners active in hospital care, hematology and iron-deficiency management.

    Dosage form: Solution for injection or infusion Strength: 50 mg/ml Therapeutic area: Blood and blood-forming organs Key indication: Iron-deficiency ...
  • Filgrastim (Commercial)

    Product Filgrastim (Commercial)

    A pre-filled syringe opportunity associated with supportive care and the management of neutropenia.

    Dosage form: Solution for injection in a pre-filled syringe Strengths: 30 MIU/0.5 ml and 48 MIU/0.8 ml Therapeutic area: Antineoplastic and immunomodulating agents ...
  • Levodropropizine Oral Liquid (Commercial)

    Product Levodropropizine Oral Liquid (Commercial)

    A complementary liquid presentation associated with the symptomatic relief of dry cough.

    Dosage form: Oral liquid Strength: 6 mg/ml Therapeutic area: Respiratory system Key indication: Symptomatic relief of dry cough Product class: Cough suppressant Dossier st...
  • Levodropropizine Tablets (Commercial)

    Product Levodropropizine Tablets (Commercial)

    An oral solid presentation associated with the symptomatic relief of dry cough.

    Dosage form: Tablet Strength: 60 mg Therapeutic area: Respiratory system Key indication: Symptomatic relief of dry cough Product class: Cough suppressant Dossier status: Available ...
  • Lisinopril (Reformulation)

    Product Lisinopril (Reformulation)

    A six-strength ACE-inhibitor opportunity undergoing reformulation.

    Dosage form: Film-coated tablet Strengths: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: ACE inhibitor Expected d...
  • Losartan (Reformulation)

    Product Losartan (Reformulation)

    A four-strength angiotensin II receptor blocker opportunity undergoing reformulation.

    Dosage form: Film-coated tablet Strengths: 12.5 mg, 25 mg, 50 mg and 100 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: Angiotensin II re...
  • Melatonin (Commercial)

    Product Melatonin (Commercial)

    A prolonged-release oral product associated with circadian-rhythm sleep disorders.

    Dosage form: Prolonged-release tablet Strength: 2 mg Therapeutic area: Nervous system Key indication: Circadian-rhythm sleep disorders Product class: Hypnotic and sedative a...
  • Out-licensing

    Product Out-licensing

    Medis is an established provider of dossiers and products in all areas of the world with launches and marketing authorizations in over 140 countries to date.
  • Palbociclib (Pipeline)

    Product Palbociclib (Pipeline)

    An oral pipeline opportunity associated with the treatment of breast cancer.

    Dosage form: Film-coated tablet Strengths: 75 mg, 100 mg and 125 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Breast cancer Product class:...
  • Pregabalin (Reformulation)

    Product Pregabalin (Reformulation)

    A broad-strength central nervous system reformulation opportunity.

    Dosage form: Hard capsule Strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg Therapeutic area: Nervous system Key indication: Neuropathic pain Product class: Analgesic Exp...

Medis ehf. resources (2)